Does transcatheter edge-to-edge repair of the mitral valve reduce hospitalization for heart failure and all-cause mortality in patients with heart failure and symptomatic moderate-to-severe or severe secondary mitral regurgitation?
Transcatheter edge-to-edge repair provides sustained 5-year benefits in reducing mortality and heart failure hospitalizations for patients with symptomatic secondary mitral regurgitation on guideline-directed medical therapy.
Among patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation who remained symptomatic despite guideline-directed medical therapy, transcatheter edge-to-edge repair of the mitral valve was safe and led to a lower rate of hospitalization for heart failure and lower all-cause mortality through 5 years of follow-up than medical therapy alone. (Funded by Abbott; COAPT ClinicalTrials.gov number, NCT01626079.).
Stone et al. (Sun,) studied this question.